Injectable hydrogels for personalized cancer immunotherapies,Acta Biomaterialia

当前位置： X-MOL 学术 › Acta Biomater. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Injectable hydrogels for personalized cancer immunotherapies
Acta Biomaterialia ( IF 9.4 ) Pub Date : 2023-10-06 , DOI: 10.1016/j.actbio.2023.10.002
Neda Mohaghegh ₁ , Amir Ahari ₂ , Fatemeh Zehtabi ₁ , Claire Buttles ₃ , Saya Davani ₁ , Hanna Hoang ₄ , Kaylee Tseng ₅ , Benjamin Zamanian ₁ , Safoora Khosravi ₆ , Ariella Daniali ₁ , Negar Hosseinzadeh Kouchehbaghi ₇ , Isabel Thomas ₁ , Hamed Serati Nouri ₈ , Danial Khorsandi ₈ , Reza Abbasgholizadeh ₁ , Mohsen Akbari ₉ , Rameshwar Patil ₁₀ , Heemin Kang ₁₁ , Vadim Jucaud ₁ , Ali Khademhosseini ₁ , Alireza Hassani Najafabadi ₁

Affiliation

Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Department of Surgery, University of California-Los Angeles, Los Angeles, CA 90095, USA.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Indiana University Bloomington, Department of Biology, Bloomington, IN 47405, USA.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90024, USA.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, California 90007, USA.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Department of Electrical and Computer Engineering, University of British Columbia, Vancouver, BC, V6T1Z4, Canada.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Department of Textile Engineering, Amirkabir University of Technology (Tehran Polytechnic), Hafez Avenue, Tehran, Iran.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Laboratory for Innovations in Microengineering (LiME), Department of Mechanical Engineering, University of Victoria, Victoria, BC V8P 5C2, Canada.
Department of Basic Science and Neurosurgery, Division of Cancer Science, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
Materials Science and Engineering, Korea University, Seoul 02841, Republic of Korea.

The field of cancer immunotherapy has shown significant growth, and researchers are now focusing on effective strategies to enhance and prolong local immunomodulation. Injectable hydrogels (IHs) have emerged as versatile platforms for encapsulating and controlling the release of small molecules and cells, drawing significant attention for their potential to enhance antitumor immune responses while inhibiting metastasis and recurrence. IHs delivering natural killer (NK) cells, T cells, and antigen-presenting cells (APCs) offer a viable method for treating cancer. Indeed, it can bypass the extracellular matrix and gradually release small molecules or cells into the tumor microenvironment, thereby boosting immune responses against cancer cells. This review provides an overview of the recent advancements in cancer immunotherapy using IHs for delivering NK cells, T cells, APCs, chemoimmunotherapy, radio-immunotherapy, and photothermal-immunotherapy. First, we introduce IHs as a delivery matrix, then summarize their applications for the local delivery of small molecules and immune cells to elicit robust anticancer immune responses. Additionally, we discuss recent progress in IHs systems used for local combination therapy, including chemoimmunotherapy, radio-immunotherapy, photothermal-immunotherapy, photodynamic-immunotherapy, and gene-immunotherapy. By comprehensively examining the utilization of IHs in cancer immunotherapy, this review aims to highlight the potential of IHs as effective carriers for immunotherapy delivery, facilitating the development of innovative strategies for cancer treatment. In addition, we demonstrate that using hydrogel-based platforms for the targeted delivery of immune cells, such as NK cells, T cells, and dendritic cells (DCs), has remarkable potential in cancer therapy. These innovative approaches have yielded substantial reductions in tumor growth, showcasing the ability of hydrogels to enhance the efficacy of immune-based treatments.

Statement of significance

As cancer immunotherapy continues to expand, the mode of therapeutic agent delivery becomes increasingly critical. This review spotlights the forward-looking progress of IHs, emphasizing their potential to revolutionize localized immunotherapy delivery. By efficiently encapsulating and controlling the release of essential immune components such as T cells, NK cells, APCs, and various therapeutic agents, IHs offer a pioneering pathway to amplify immune reactions, moderate metastasis, and reduce recurrence. Their adaptability further shines when considering their role in emerging combination therapies, including chemoimmunotherapy, radio-immunotherapy, and photothermal-immunotherapy. Understanding IHs' significance in cancer therapy is essential, suggesting a shift in cancer treatment dynamics and heralding a novel period of focused, enduring, and powerful therapeutic strategies.

中文翻译：

用于个性化癌症免疫治疗的可注射水凝胶

癌症免疫治疗领域已显示出显着增长，研究人员现在正专注于增强和延长局部免疫调节的有效策略。可注射水凝胶（IHs）已成为封装和控制小分子和细胞释放的多功能平台，因其在抑制转移和复发的同时增强抗肿瘤免疫反应的潜力而受到广泛关注。递送自然杀伤（NK）细胞、T 细胞和抗原呈递细胞（APC）的 IH 为治疗癌症提供了一种可行的方法。事实上，它可以绕过细胞外基质，逐渐将小分子或细胞释放到肿瘤微环境中，从而增强对癌细胞的免疫反应。本综述概述了使用 IHs 递送 NK 细胞、T 细胞、APC、化学免疫疗法、放射免疫疗法和光热免疫疗法的癌症免疫疗法的最新进展。首先，我们介绍 IHs 作为递送基质，然后总结它们在小分子和免疫细胞局部递送以引发强大的抗癌免疫反应中的应用。此外，我们还讨论了用于局部联合治疗的 IHs 系统的最新进展，包括化学免疫疗法、放射免疫疗法、光热免疫疗法、光动力免疫疗法和基因免疫疗法。通过全面研究 IHs 在癌症免疫治疗中的利用，本综述旨在强调 IHs 作为免疫治疗有效载体的潜力，促进癌症治疗创新策略的开发。此外，我们证明，使用基于水凝胶的平台靶向递送免疫细胞，如 NK 细胞、T 细胞和树突状细胞（DC），在癌症治疗中具有显着的潜力。这些创新方法已显着减少肿瘤生长，展示了水凝胶增强免疫治疗疗效的能力。

重要性声明

随着癌症免疫疗法的不断发展，治疗药物的递送模式变得越来越重要。本综述重点介绍了 IHs 的前瞻性进展，强调了它们彻底改变局部免疫治疗递送的潜力。通过有效封装和控制 T 细胞、NK 细胞、APC 和各种治疗剂等基本免疫成分的释放，IH 为放大免疫反应、中度转移和减少复发提供了开创性的途径。当考虑到它们在新兴联合疗法（包括化学免疫疗法、放射免疫疗法和光热免疫疗法）中的作用时，它们的适应性进一步显现。了解 IHs 在癌症治疗中的重要性至关重要，这表明癌症治疗动态发生了转变，并预示着一个集中、持久和强大的治疗策略的新时期。

更新日期：2023-10-06

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南